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Endothelial dysfunction predicts cardiovascular disease1 and is 
central to the development and progression of atherosclerosis.2 
Similarly, oxidative stress and inflammation are believed to play 
a role in atherosclerosis and have been shown to modulate the 
nitric oxide (NO) system.3 Considering the growing health bur-
den of cardiovascular disease, risk factors that could influence 
endothelial function, inflammation, and oxidative stress are of 
great interest, such as uric acid. Uric acid is generated by the liver 
and other peripheral tissues as a normal byproduct of purine 
metabolism. Recent studies have highlighted a potential role for 
elevated serum uric acid levels in cardiovascular disease.4
Although the association between serum uric acid levels and 
ischemic  cardiovascular  disease  is  well-established  in  several 
large epidemiological studies,5–7 controversy exists to whether 
this association is causal.8,9 On one hand, under physiological 
concentrations, urate (the soluble form of uric acid) is a power-
ful antioxidant that can scavenge superoxide, hydroxyl radicals, 
and singlet oxygen.10 In addition, xanthine oxidase, the enzyme 
that converts hypoxanthine to xanthine, and xanthine to uric 
acid, also generates reactive oxidative species and may play a role 
in vascular disease11 suggesting that uric acid is merely a marker 
for disease. Alternatively, uric acid can react with NO irreversibly 
in vitro leading NO depletion12 and may cause oxidative stress 
once internalized by the cells.13 In vascular smooth muscle cells, 
uric acid induces inflammatory mediators such as C-reactive 
protein (CRP) and activates nuclear factor-κB (NF-κB).14,15 In 
some animal models, even mild elevation in uric acid levels has 
been reported to induce endothelial dysfunction16 and inflam-
matory cytokines,17 while other animal studies have shown the 
opposite.18 Similarly, it remains unclear if circulating uric acid 
concentrations are related to endothelial function among healthy 
adults.19,20 Importantly, the relation between uric acid and mark-
ers of inflammation and oxidative stress in endothelial cells (ECs) 
obtained in vivo from humans is unknown.
Hence,  we  hypothesized  that  increased  serum  uric  acid   
levels are associated with impaired endothelial function and 
with increased systemic and cellular inflammation and oxida-
tive stress in healthy adults. We used a community based cohort 
in  Boulder,  Colorado  to  test  our  hypothesis.  Endothelial-
dependant  dilation  (EDD)  was  assessed  by  brachial  artery 
flow-mediated dilation and endothelial-independent dilation 
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Background
Some experimental evidence suggests that uric acid impairs 
endothelial function. it is controversial if high uric acid levels and 
impaired endothelial function are related in healthy adults. in addition, 
the effect of uric acid on endothelial cells (ECs) of humans is unexplored.
Methods
Data of 107 healthy adult volunteers were analyzed. The association 
between serum uric acid and endothelial-dependant dilation (EDD) 
and endothelial-independent dilation (EiD) was evaluated by linear 
regression models. We also examined the relations between uric acid 
and systemic and cellular markers of inflammation and oxidative 
stress in all or subsets of participants.
results
Uric acid levels and EDD were not related in unadjusted or adjusted 
models. There was a significant negative correlation between 
uric acid and EiD in the pooled sample (r = −0.34, P = 0.005). This 
correlation remained significant after adjusting for demographics 
(P = 0.04) and was attenuated after adjusting for other cardiac 
risk factors (P = 0.12). Higher serum uric acid levels were found to 
correlate significantly with C-reactive protein (CRp) (r = 0.31,  
P = 0.002). Serum uric acid levels were not associated with brachial 
artery EC nuclear factor-κB (NF-κB) p65 or NaDpH oxidase p47phox 
expression or with nitrotyrosine staining, but were inversely 
associated with EC manganese superoxide dismutase (MnSOD) 
expression (r = −0.5, P = 0.01, n = 25).
conclusion
Elevated serum uric acid is not associated with endothelial dysfunction 
among healthy adults, but is inversely related to EiD and EC MnSOD, 
and positively related to systemic inflammation. These findings may 
have implications for cardiovascular risk in healthy adults.
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(EID) was assessed by change in diameter after nitroglycerin 
(NTG) administration. ECs were collected from the brachial 
arteries of the participants and immunofluorescence was per-
formed for markers of inflammation and oxidative stress.
Methods
Study population. Data for this analysis were collected as part 
of a community-based study in Boulder, Colorado. The analysis 
included 107 adult participants (20–78 years) who had complete 
data on EDD and serum uric acid levels. Subjects were healthy 
with no history of diabetes, hypertension, or known cardiovas-
cular disease, as assessed by history, physical examination, bio-
chemical tests, and electrocardiogram. None of the subjects were 
smokers or taking medications (prescription or over the counter 
medications), hormone replacement therapy, or dietary supple-
ments (including those with antioxidant properties). All proce-
dures were approved by the Human Research Committee of the 
University of Colorado at Boulder. The nature, benefits, and risks 
of the study were explained to the volunteers, and their written 
informed consent was obtained before participation.
Predictor and outcome. The independent variable of interest was 
serum uric acid levels (mg/dl). Serum uric acid levels were meas-
ured on stored baseline samples via the Clinical Analyzer utiliz-
ing an uricase-based commercial kit as previously described.21
The dependant variable of interest was EDD estimated via 
brachial artery flow-mediated dilation with upper forearm cuff 
position. In addition, we examined the association between uric 
acid and EID assessed by measurement of brachial artery dila-
tion in response to sublingual NTG given at a dose of 0.4 mg. 
Baseline shear rate, peak shear rate during flow-mediated dila-
tion  (FMD),  and  EID  were  determined  using  duplex  ultra-
sonography (Power Vision 6000; Toshiba, Tochigi, Japan) with a 
linear array transducer as described previously.22 Responses are 
expressed as absolute (mm) and percent change from baseline 
diameter as per recent guidelines (see Supplementary Materials 
and Methods and Supplementary Tables S1 and S2 online).23
Other  outcomes.  To  examine  the  association  between  serum 
uric acid levels and systemic inflammation and oxidative stress, 
we elected CRP and oxidized low-density lipoprotein (oxLDL), 
respectively.  CRP  was  measured  by  an  Olympus  AU400e 
Chemistry Analyzer (Olympus, Melville, NY) and is reported in 
mg/l. oxLDL was determined with an ELISA plate assay (Alpco 
Diagnostics, Salem, NH) and is reported as U/l.
We  then  sought  to  understand  the  relationship  between 
serum uric acid levels and markers of inflammation and oxi-
dative stress in ECs of the participants. NF-κB p65 subunit 
(n = 35) and NADPH oxidase enzyme subunit p47phox (n = 32) 
were evaluated due to prior literature suggesting they mediate 
uric acid-induced injury.15,24 To obtain a more comprehen-
sive understanding of cellular oxidative stress, in addition to 
staining for pro-oxidant NADPH oxidase p47phox, we stained 
for the antioxidant enzyme manganese superoxide dismutase 
(MnSOD) (n = 25). Nitrotyrosine (n = 43) was also evalu-
ated as a marker of oxidative damage. The ECs were   collected 
as  previously  described,25  and  the  detailed  methods  are 
included in the Supplementary Materials and Methods and 
Supplementary Tables S1 and S2 online. The small number 
of participants with immunostaining is due to the difficulty of 
obtaining molecular data in humans.
Other covariates. Covariates were selected for inclusion in the 
multivariate model-based on their physiological relevance and 
the literature. Demographics included were: age (years), gender 
(male vs. female), and ethnicity (Caucasian, Hispanic, Asian, and 
African American). Body mass index (BMI) was calculated from 
height and weight to the nearest 0.1 kg. To account for central 
obesity, waist circumference (cm) was included. Arterial blood 
pressure was measured over the brachial artery during seated 
rest using a semiautomated device (Dynamap XL; Johnson & 
Johnson, New Brunswick, NJ).26 Plasma low-density lipoprotein 
cholesterol and glucose were determined using standard assays 
and are reported in mg/dl. All measurements were performed at 
the University of Colorado at Boulder Clinical and Translational 
Research Center after an overnight fast (water only) and a 24-h 
abstention from alcohol and vigorous physical activity. Chronic 
alcohol intake was not correlated with EDD or with serum uric 
acid levels and as such was not included in the final model.
Statistical  analysis.  ANOVA  with  a  Tukey–Kramer  P  value 
adjustment was used to compare covariates among quartiles of 
uric acid. χ2-test of independence was used to compare categori-
cal variables among quartiles of uric acid. In order to examine 
the association of serum uric acid levels and vascular function, 
serum uric acid levels were modeled as a continuous variable in 
univariate and multivariate models. For n = 107, we calculated 
that we had 80% power to detect a correlation r = 0.267 with a 
two-sided α = 0.05. Multiple linear regression was used to test 
for a linear relationship of uric acid with FMD % Δ and NTG 
dilation % Δ. Two sequential sets of covariates were considered. 
In model 1, the covariates included age, gender, and ethnicity. In 
model 2, the covariates included those in model 1 in addition 
to BMI, waist circumference, systolic blood pressure, low-density 
lipoprotein cholesterol, fasting blood glucose, and baseline diam-
eter. A detailed description of the number of participants in each 
model is included in the Supplementary Materials and Methods 
and Supplementary Tables S1 and S2 online. Scatter plots and 
Pearson correlation coefficients were used to show the unad-
justed relationship of uric acid with EDD (FMD % Δ) and EID 
(NTG % Δ). The correlation between uric and CRP and oxLDL 
was examined using unadjusted and adjusted linear regression. 
Similarly, linear regression was employed to examine the relation 
between uric acid levels and the immunostains designated above. 
All analyses were conducted using SAS 9.2 (Research Triangle 
Institute, Research Triangle Park, NC). P < 0.05 was considered 
statistically significant.
results
characteristics of participants by serum uric acid quartile
Characteristics of the participants according to quartiles of 
uric acid are shown in Table 1. Individuals with the highest AMERICAN JOURNAL OF HYPERTENSION | VOLUME 25 NUMBER 4 | apRiL 2012     409
original contributions Uric Acid and Vascular Function
quartile of uric acid were older and more likely to be male 
when compared to the lowest quartile of uric acid. Higher 
serum uric acid levels were associated with significantly higher 
BMI and fasting blood glucose levels. There were no significant   
differences in EDD (FMD % Δ) across increasing uric acid 
levels. However, there was a tendency for EID (NTG % Δ) to 
decrease across increasing quartiles of uric acid. This tendency 
did not achieve statistical significance (P = 0.09). Serum CRP 
levels increased significantly with increased uric acid quar-
tiles (P < 0.005). There was a trend towards increased oxLDL   
levels with increasing serum uric acid levels but these differ-
ences were not found to be statistically significant.
association between serum uric acid levels and edd (FMd % Δ)
There was no correlation between serum uric acid levels and FMD 
as depicted in Figure 1a; the unadjusted Pearson correlation was r 
= 0.07, P = 0.46. Similarly, multiple linear regression adjusting for 
age, gender, and ethnicity (model 1) demonstrated no correlation 
between uric acid and FMD % Δ (β = –0.03 ± 0.25, P = 0.89), and 
linear regression adjusting for age, gender, ethnicity, BMI, waist 
circumference, systolic blood pressure, low-density lipoprotein 
cholesterol, and fasting blood glucose (model 2) demonstrated 
no correlation between uric acid and FMD % Δ (β = 0.05 ± 0.27,   
P = 0.86).
association between serum uric acid levels and eid (ntg % Δ)
Seventy  subjects  had  no  contraindication  to  NTG  admin-
istration  and  underwent  EID  measurement.  Results  of  the 
unadjusted analysis are shown in Figure 1b. The unadjusted 
correlation between uric acid and NTG dilation % was r = –0.34, 
P = 0.005. The association between serum uric acid levels and 
EID remained significant after adjusting for age, gender, and 
ethnicity (β = –1.57 ± 0.75, P = 0.04; model 1). There was a 
negative correlation between uric acid and NTG dilation % 
after adjusting for all other covariates, but this did not achieve 
statistical significance (β = –1.25 ± 0.80, P = 0.12; model 2).
relationship between serum uric acid levels and markers of 
systemic inflammation and oxidative stress
Linear regression was initially performed between uric acid and 
CPR levels both as continuous variables, and on initial analysis 
there were some highly influential points. This was confirmed 
by influence diagnostics. Hence, a log 10 transformation was 
applied and a better fit was obtained. In Figure 2, we show 
that there is a significant relationship between uric acid and 
CRP with a correlation coefficient of 0.31 (P = 0.002) in unad-
justed analysis. This relation was attenuated after adjusting for 
age, gender, and ethnicity (P = 0.28), and remained not signifi-
cant after adjusting for all the covariates included in model 2 
table 1 | subject characteristics according to serum uric acid quartiles (mg/dl)
1st Quartile (N = 30) 2nd Quartile (N = 23) 3rd Quartile (N = 31) 4th Quartile (N = 23)
UA (<5.3) UA (5.3–6.1) UA (6.2–7.0) UA (>7.0)
age (years) 54.5 ± 14.4 55.9 ± 13.7 55.3 ± 15.1 59.5 ± 12.1
Gender (male) 11/30 (36.7%) 15/23 (65.2%) 22/31 (71.0%) 20/23 (87%)*
% postmenopausal (90%) (89%) (100%) (100%)
Ethnicity
  Caucasian 29 23 29 19
  Hispanic 0 0 0 1
  asian 1 0 1 1
  african american 0 0 1 1
BMi (kg/m2) 24.4 ± 3.96 25.5 ± 4.97 26.1 ± 3.26 27.6 ± 4.53**
Waist circumference (cm) 79 ± 10 88 ± 15 88 ± 10 96 ± 14
SBp (mm Hg) 118 ± 17 118 ± 18 118 ± 14 126 ± 14
LDL-C (mg/dl) 117 ± 25 117 ± 32 119 ± 30 127 ± 33
Fasting glucose (mg/dl) 86 ± 5 90 ± 9 91 ± 8 95 ± 9***
Baseline diameter (cm) 3.37 ± 0.51 3.80 ± 0.70 3.75 ± 0.75 4.00 ± 0.49**
FMD absolute Δ 0.20 ± 0.10 0.19 ± 0.09 0.24 ± 0.11 0.19 ± 0.09
FMD % Δ 5.93 ± 3.13 5.55 ± 3.2 6.31 ± 2.81 4.74 ± 2.17
NTG absolute Δ 0.94 ± 0.25 1.04 ± 0.22 0.86 ± 0.20 0.89 ± 0.17
NTG- dilation % Δ 28.5 ± 8.15 28.2 ± 7.34 23.3 ± 5.52 22.7 ± 5.67
Baseline CRp (mg/l) 0.73 ± 0.55 0.92 ± 0.81 0.96 ± 0.78 3.83 ± 6.10***
oxLDL (U/l) 55.66 ± 16.02 57.04 ± 13.56 55.62 ± 14.73 60.34 ± 18.20
Values are expressed as means ± s.d.
%, percent of patients; BMI, body mass index; CRP, C-reactive protein; FMD % Δ, % change in flow-mediated dilation; LDL-C, low density lipoprotein cholesterol; NTG, nitroglycerin;  
oxLDL, oxidized low-density lipoprotein; SBP, systolic blood pressure; UA, uric acid.
*χ2 = 7.1 for gender (P = 0.0014); **P < 0.05 quartile 1 vs. quartile 4; ***P < 0.005 for quartile 1 vs. quartile 4.410     apRiL 2012 | VOLUME 25 NUMBER 4 | AMERICAN JOURNAL OF HYPERTENSION
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(P = 0.43). Consistent with our findings in Table 1, there was 
no correlation between serum uric acid levels and oxLDL when 
they were both examined as continuous variables (P = 0.43 in 
unadjusted analysis, and P = 0.82 in the fully-adjusted model).
relation between serum uric acid levels and ecs markers of 
inflammation and oxidative stress
There was no correlation between serum uric acid levels and 
the expression of NF-κB p65 or NADPH oxidase p47phox or 
nitrotyrosine staining in brachial artery ECs. In contrast, we 
found that higher uric acid levels were inversely related to the 
expression of MnSOD in our participants with a correlation 
coefficient of –0.50 and a P value of 0.01. The scatter plot is 
shown in Figure 3. To further illustrate our findings, mean   
values  and  representative  images  of  the  immunostains  are 
shown  according  to  serum  uric  acid  quartiles  in  Figure 4. 
Descriptive  data  for  the  subgroup  with  available  MnSOD 
staining (n = 25) are shown in Table 2.
discussion
In the current analysis, we explored the potential association 
between  uric  acid  and  vascular  function  in  healthy  adults. 
Our  study  is  the  first  attempt  to  correlate  uric  acid  levels 
with molecular changes in ECs of healthy adults. We found 
that serum uric acid levels are not correlated with EDD in 
unadjusted  or  adjusted  analysis,  despite  a  significant  posi-
tive  correlation  between  serum  uric  acid  levels  and  CRP   
levels (in unadjusted linear regression). On the cellular level we 
found no correlation between uric acid levels and NF-κB p65, 
NADPH oxidase p47phox, or nitrotyrosine. However, there was 
a significant inverse relation between serum uric acid and the 
expression of the antioxidant enzyme MnSOD.
The controversy surrounding the relation between uric acid 
and endothelial dysfunction has been fueled to some extent by 
the negative findings of some studies in healthy controls. For 
example, induced hyperuricemia did not impair endothelial 
function in a group of healthy controls.20 Similarly, a prior 
study by our group found that xanthine oxidase inhibition by 
allopurinol lowered uric acid levels but did not improve EDD 
in healthy subjects.27 Both of these studies assessed the effects 
of uric acid and allopurinol on endothelial function acutely 
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Figure 1 | Scatter plots for vascular function measurements against uric acid 
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rather than chronically. But our current observations are in 
agreement with these prior negative studies and suggest that 
hyperuricemia alone is not an effective mediator of endothelial 
dysfunction. Consistent with this conclusion, no correlation 
was found between uric acid levels and cellular NF-κB p65, 
NADPH oxidase p47phox, or nitrotyrosine (markers of endothe-
lial inflammation and oxidative stress).
The dissociation between the expression of MnSOD and 
EDD in our study is intriguing. MnSOD is a member of the 
superoxide dismutase family of enzymes that play an impor-
tant role in the regulation of local superoxide levels and have 
a protective effect. Homozygous MnSOD-deficient mice die 
in the neonatal period, suggesting that MnSOD is a key reg-
ulator of oxidative stress.28 Consistent with such a role, het-
erozygous MnSOD-deficient mice show greater endothelial 
dysfunction than wild-type mice in models of aging29 and 
heart  failure.30  Yet,  heterozygous  MnSOD-deficient  mice 
exhibit similar vasomotor responses to wild type mice under 
normal  conditions,31  suggesting  that  MnSOD  deficiency 
alone is insufficient to induce vascular dysfunction. As such, 
reduced MnSOD activity may impair the host’s ability to cope 
with increased oxidative stress associated with certain condi-
tions. Our study population is a healthy population (with no 
evidence of hypertension or diabetes). This could explain why 
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Figure 4 | Expression of markers of inflammation and oxidative stress in brachial artery endothelial cells according to serum uric acid quartiles. Values represent 
ratios of subject endothelial protein expression to HUVEC control, and are shown as mean ± s.d. Unpaired t-test with Welch’s correction was used to compare the 
expression between the 1st quartile and the 2nd, 3rd, or 4th quartiles. The number of available stains is depicted on each figure. (a) NF-κB expression (n = 35),  
(b) nitrotyrosine abundance (n = 43), (c) NaDpH oxidase protein expression (n = 32), and (d) manganese superoxide dismutase (MnSOD) protein expression  
(n = 25). *P = 0.04 and #P = 0.006 both in comparison to the lowest uric acid quartile (<5.3 mg/dl). Ua, uric acid. 
table 2 | characteristics of the subjects with available staining 
for Mnsod
(N = 25)
age (years) 60.7 ± 4.1
Gender (male) 11 (44.0%)
Ethnicity
  Caucasian 24 (96%)
  Missing 1 (4%)
Uric acid (mg/dl) 6.26 ± 1.11
BMi (kg/m2) 26.1 ± 3.5
Waist circumference (cm) 86.2 ± 14
SBp (mm Hg) 121.9 ± 17.0
LDL-C (mg/dl) 125.8 ± 28.6
Fasting glucose (mg/dl) 88.5 ± 7.3
Baseline CRp (mg/l) 1.3 ± 0.9
oxLDL (U/l) 54.1 ± 10.5
Values are expressed as means ± s.d.
%, percent of patients; BMI, body mass index; CRP, C-reactive protein; LDL-C, low-density 
lipoprotein cholesterol; MnSOD, manganese superoxide dismutase; oxLDL, oxidized 
low-density lipoprotein; SBP, systolic blood pressure.412     apRiL 2012 | VOLUME 25 NUMBER 4 | AMERICAN JOURNAL OF HYPERTENSION
original contributions Uric Acid and Vascular Function
the effect of uric acid on MnSOD expression was unaccom-
panied by significant changes in endothelial function in this 
analysis. After all uric acid appears to be a stronger predic-
tor of risk in high risk groups such as African Americans,32 
patients  with  underlying  hypertension,33  congestive  heart 
failure,34 and chronic kidney disease.35 Along the same lines, 
these findings could reconcile the different findings of stud-
ies on the topic in healthy subjects. In settings in which uric 
acid is related to endothelial dysfunction,19 other factors that 
modify the oxidative state may be involved such as sedentary 
lifestyle or higher dietary intake of pro-oxidants.
Another interesting observation in our study is the dissocia-
tion between systemic and cellular inflammation. Considering 
the  in  vitro  evidence  that  CRP  induces  ECs  dysfunction,36 
these  finding  seem  counterintuitive.  However,  there  is  evi-
dence to indicate that certain biochemical characters of ECs are 
induced by CRP only in the presence of an additional adverse 
factors such as aldosterone,37 suggesting that high risk popula-
tions are more likely to see the ill effects of any one mediator. 
Another explanation for our data may be that systemic inflam-
mation does not always reflect cell-, tissue- or organ-specific 
inflammation.
Rather than EDD, we found an association between uric acid 
and EID. This association remained significant after adjusting 
for demographics, and was attenuated after adjusting for poten-
tial mechanisms such as systolic blood pressure, serum glu-
cose, and LDL cholesterol. These findings are consistent with 
previous studies in which uric acid has been shown to induce 
inflammation (including CRP expression) in cultured vascular 
smooth muscle cells by activating the mitogen-activated protein 
kinase pathway.14 In turn, activation of the mitogen-activated 
protein kinase pathway has been shown to play a role in vas-
cular smooth muscle proliferation.38 Differential associations 
between cardiovascular risk factors and EDD and EID have 
been reported in the literature. Notably, lower EID as opposed 
to EDD has been reported in association with various other ele-
ments of the metabolic syndrome such as insulin resistance, 
increased triglycerides, and higher BMI.39,40 Our findings are 
consistent with these previous reports, and suggest that uric 
acid correlates with reduced vascular smooth muscle sensitiv-
ity to NO. One potential explanation for the lack of correla-
tion between uric acid and EDD despite the in vitro evidence 
for uric acid suppressing NO bioavailability, is that individu-
als with mild hyperuricemia may have greater compensatory 
flow-mediated dilation in response to non-NO endothelium-
synthesized dilator molecules such as vasodilatory prostaglan-
dins and/or endothelium-dependent hyperpolarizing factors.41 
Alternatively, uric acid may modulate the response to NO dif-
ferently in endothelial vs. vascular smooth muscle cells.
Our  study  has  several  limitations.  First  this  is  a  cross-
sectional  observational  study  rather  than  an  interventional 
study, and cause and effect between uric acid and inflamma-
tion and oxidative stress or EID cannot be established based 
on such an analysis. Second, the majority of participants with 
elevated uric acid in our study were men, and uric acid may be 
a stronger risk factor for cardiovascular disease in women.42 
Of note, an interaction term for gender was not significant. 
In addition, the majority of our participants had mild hype-
ruricemia and we cannot exclude a relation between severe 
hyperuricemia and endothelial dysfunction in healthy adults 
based on our results.43 Finally, the number of participants with 
immunostaining of ECs was small and although the relation-
ship between uric acid levels and MnSOD is striking, other 
studies are needed to verify our findings.
In  conclusion,  uric  acid  is  not  associated  with  vascular 
endothelial  dysfunction  in  healthy  adults.  Although  serum 
uric acid levels correlated with circulating CRP in our popu-
lation, there was no correlation between serum uric acid and 
the expression of cellular markers of inflammation. Increased 
serum uric acid levels, however, were associated with reduced 
ECs expression of the antioxidant enzyme, MnSOD. In addi-
tion increased uric acid levels were associated with reduced 
vascular smooth muscle sensitivity to NO. These findings may 
help explain the inconsistent association between uric acid and 
endothelial dysfunction in different studies.
Supplementary material is linked to the online version of the paper at http://
www.nature.com/ajh
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